Explorez tous les épisodes du podcast Psychopharmacology and Psychiatry Updates
| Titre | Date | Durée | |
|---|---|---|---|
| SSRIs and Kids: Escitalopram for Pediatric Anxiety | 29 Aug 2024 | 00:11:47 | |
In this episode, we explore a groundbreaking study on escitalopram's efficacy in treating generalized anxiety disorder in children and adolescents. We discuss its potential as the first FDA-approved medication for youth anxiety. How might this change our approach to pediatric anxiety treatment? Faculty: David Rosenberg, M.D. | |||
| Unraveling Treatment Resistance: A Psychodynamic Approach | 24 Aug 2024 | 00:13:34 | |
In this episode, we explore psychodynamic psychopharmacology and its role in addressing treatment-resistant cases. We discuss how patient-doctor relationships, transference, and countertransference can impact medication effectiveness. How might your own unconscious biases influence your prescribing decisions? Faculty: David Mintz, M.D. | |||
| Restoring Sleep in Major Depression: Orexin, Melatonin, and More | 10 Jul 2024 | 00:10:51 | |
In this episode, we explore the latest pharmacologic interventions for managing insomnia in patients with major depressive disorder. Can dual orexin receptor antagonists, melatonin agonists, and low-dose doxepin provide relief for those struggling with sleep? Join us as we discuss the advances in treating insomnia and depression. Faculty: Amit Chopra, M.D. | |||
| Enhancing Pediatric Depression Treatment: The Role of Fish Oil and CBT | 05 Jul 2024 | 00:11:38 | |
In this episode, we explore the potential of fish oil as an adjunct to cognitive–behavioral therapy for treating depression in youth. Can this combination enhance treatment outcomes, or is cognitive–behavioral therapy alone just as effective? Join us as we dive into this intriguing study. Faculty: David Rosenberg, M.D. | |||
| Pharmacological Strategies for Insomnia in MDD | 30 Jun 2024 | 00:12:06 | |
In this episode, we explore the use of benzodiazepines and nonbenzodiazepine hypnotics for managing insomnia in major depressive disorder. How do these medications work, and what are the key considerations when prescribing them? Join us as we navigate the complexities of pharmacologic interventions for insomnia. Faculty: Amit Chopra, M.D. | |||
| Balancing Benefits and Risks: Antipsychotics in Hepatic Dysfunction | 25 Jun 2024 | 00:11:10 | |
In this episode, we explore the safety of antipsychotics in patients with liver disease. How can psychiatrists navigate the risk–benefit balance when treating medically complex individuals? Dr. Sydney LeFay discusses key insights from a recent review article, guiding antipsychotic selection and monitoring. Faculty: Sydney LeFay, D.O. | |||
| Insomnia and Depression: A Tangled Web | 20 Jun 2024 | 00:16:01 | |
In this episode, we explore the complex relationship between insomnia and major depressive disorder. How does insomnia impact the course and treatment of depression? Join us as we dive into the neurobiology and clinical implications of this fascinating topic with expert Dr. Amit Chopra. Faculty: Amit Chopra, M.D. | |||
| ADHD Treatment During Pregnancy: Insights from Denmark | 15 Jun 2024 | 00:09:19 | |
In this episode, we explore the long-term effects of ADHD medication use during pregnancy on children's development. Can continuing treatment pose risks, or is it safer than previously thought? Join us as we dive into a groundbreaking Danish study that sheds light on this critical question.
| |||
| The Power of Nonpharmacologic Therapies in Fibromyalgia | 10 Jun 2024 | 00:08:52 | |
In this episode, we explore the growing evidence for nonpharmacologic therapies in managing fibromyalgia symptoms. Could a combination of exercise, cognitive–behavioral therapy, and integrative approaches, like acupuncture or yoga, be the key to better outcomes for patients resistant to traditional treatments? Faculty: Daniel Clauw, M.D. | |||
| Highlights From APA 2024: Key Insights on Psychopharmacology | 05 Jun 2024 | 00:18:17 | |
In this episode, the editorial team of the Psychopharmacology Institute discusses 3 important topics presented at the APA Annual Meeting: Prescribing psychiatric medications during pregnancy, recent advances in clozapine treatment, and managing eating disorders, namely anorexia nervosa and bulimia nervosa. The episode covers the safety and dose adjustments for medications like SSRIs, lamotrigine, and lithium during pregnancy; early initiation and monitoring of clozapine; and effective treatments, including psychotherapy, olanzapine, and fluoxetine for eating disorders. Hosts: Flavio Guzman, M.D., Paz Badia, M.D., and Lorena Rodriguez, M.D.
| |||
| Antidepressants in Pregnancy: Weighing the Evidence | 31 May 2024 | 00:11:24 | |
In this episode, we discuss a new study on maternal depression, antidepressant use, and pregnancy complications. Can antidepressants during pregnancy harm the baby? Dr. Lauren Osborne helps us weigh the risks and benefits. Faculty: Lauren Osborne, M.D. | |||
| Unraveling the Pharmacological Puzzle of Fibromyalgia | 26 May 2024 | 00:08:16 | |
In this episode, we explore the most effective pharmacologic treatments for fibromyalgia, a complex nociplastic pain syndrome. Dr. Daniel Clauw shares his insights on the top drug classes for managing fibromyalgia and discusses why opioids should be avoided. Could the hyperactive endogenous opioid system in fibromyalgia patients explain the ineffectiveness of opioids? Faculty: Daniel Claw, M.D. | |||
| Psychedelics: A New Frontier in Psychiatry | 19 Aug 2024 | 00:10:53 | |
In this episode, we explore the therapeutic potential of psychedelic compounds in psychiatry. We discuss their definition, mechanism of action, and potential uses in treating anxiety and depression. How might psychedelics reshape the future of psychopharmacology? Faculty: Sidney LeFay, D.O. | |||
| Beyond the Prescription Pad: Navigating Patient Ambivalence | 14 Aug 2024 | 00:12:09 | |
In this episode, we explore the concept of patient ambivalence in psychopharmacology. How can understanding a patient's conflicting feelings about treatment improve outcomes? We discuss strategies for recognizing and addressing ambivalence, and its impact on medication adherence and effectiveness. Faculty: David Mintz, M.D. | |||
| Unplugging from Vaping: Cessation Strategies for Teens | 09 Aug 2024 | 00:10:53 | |
In this episode, we explore vaping cessation methods used by US adolescent e-cigarette users. We discuss a study analyzing the prevalence and effectiveness of various quitting strategies, considering factors like demographics and perception of harm. How can healthcare providers tailor their approach to help teens quit vaping? Faculty: David Rosenberg, M.D. | |||
| When Drugs Don't Work: A Psychodynamic Approach | 04 Aug 2024 | 00:11:12 | |
In this episode, we explore Psychodynamic Psychopharmacology, an innovative approach to treating medication-resistant patients. We discuss how psychological factors influence drug responses and learn techniques to enhance treatment outcomes. Could understanding the meaning patients attach to their medications be the key to unlocking treatment resistance? Faculty: David Mintz, M.D. | |||
| Rethinking Rx: Benzodiazepines and Suicide Risk | 30 Jul 2024 | 00:09:43 | |
In this episode, we explore the complex relationship between benzodiazepine use and suicide risk, examining a groundbreaking French study that challenges our understanding of this connection. Is our go-to anxiety treatment potentially increasing suicide risk? Faculty: Paul Zarkowski, M.D. | |||
| The Psychology of Prescribing: Optimizing Outcomes Through Understanding | 25 Jul 2024 | 00:14:36 | |
In this episode, we explore how a psychodynamic approach can shed light on treatment-resistant cases. Can understanding a patient's psychological dynamics be the key to unlocking better outcomes? Faculty: David Mintz, M.D. | |||
| ADHD and Pain: A Surprising Link | 20 Jul 2024 | 00:11:59 | |
In this episode, we explore the fascinating connection between ADHD, pain sensitivity, and methylphenidate treatment in children. Could methylphenidate help reduce pain sensitivity in pediatric ADHD patients? Faculty: David Rosenberg, M.D. | |||
| Restoring Rest: Insomnia Interventions for Depressed Patients | 15 Jul 2024 | 00:15:08 | |
In this episode, we dive into the complex world of treating insomnia in patients with major depressive disorder. What's the best approach to help these patients find restful sleep and improve their mood? Join us as we explore a range of strategies, from medication to behavioral interventions. Faculty: Amit Chopra, M.D. | |||
| Debunking Myths: Lithium Use in Pregnancy | 03 Sep 2024 | 00:10:47 | |
In this episode, we explore the risks and benefits of using lithium during pregnancy for women with bipolar disorder. We discuss recent research on cardiac malformations and dose-dependent risks. Is the fear of lithium use in pregnancy justified by the latest evidence? Faculty: Vivien Burt, M.D. | |||
| SSRIs and Psychedelics: Drug Interactions | 03 Oct 2025 | 00:11:14 | |
In this episode, we explore the complex drug-drug interactions between psychedelics and psychiatric medications. Do SSRIs really blunt psychedelic effects, or is this just clinical folklore? We'll examine surprising new research and discuss potentially dangerous combinations every psychiatrist should know. Faculty: Franklin King, M.D. | |||
| Standard vs. High Doses: Rethinking Bipolar Maintenance Treatment | 28 Sep 2025 | 00:14:06 | |
In this episode, we challenge the conventional wisdom of “what gets them well keeps them well” by exploring groundbreaking Finnish research on bipolar disorder medication dosing. Does maintaining patients on high doses actually improve long-term outcomes, or could standard doses be the optimal strategy for relapse prevention? Faculty: Kristin Raj, M.D. | |||
| Antidepressants Beyond Depression: Applications in Bulimia Nervosa | 14 Aug 2025 | 00:09:28 | |
In this episode, we explore evidence-based pharmacotherapy for bulimia nervosa, including why higher doses of SSRIs work better than standard dosing, which medications to avoid completely, and how antidepressants can be effective even without depression being present. Why does fluoxetine require 60 mg daily for optimal results? Faculty: Scott Crow M.D. | |||
| Metformin and Antipsychotic-Induced Weight Gain: An Evidence-Based Solution | 09 Aug 2025 | 00:12:10 | |
In this episode, we explore groundbreaking research on managing antipsychotic-induced weight gain through a comprehensive network meta-analysis. Could the combination of low-dose metformin and lifestyle modifications be the game-changer that helps patients maintain both mental stability and physical health? Faculty: Scott Beach, M.D. | |||
| Monthly Injections, Long-Term Recovery: Naltrexone for OUD | 04 Aug 2025 | 00:08:17 | |
In this episode, we explore extended-release naltrexone for opioid use disorder, examining its unique role as a pure antagonist in patients who require safety-sensitive careers. How do we successfully navigate the challenging initiation period when patients must be opioid-free for a week?
| |||
| Antipsychotics and Aspiration Risk | 30 Jul 2025 | 00:12:03 | |
In this episode, we explore the surprising link between antipsychotic medications and pneumonia risk. Did you know that pneumonia is the fourth leading cause of death in schizophrenia patients, and certain medications increase this risk in unexpected ways? Faculty: Scott Beach, M.D. | |||
| Buprenorphine, Methadone, and Naltrexone: Helping Patients with OUD Decide | 25 Jul 2025 | 00:11:10 | |
In this episode, we explore how to choose between methadone, buprenorphine, and naltrexone for opioid use disorder treatment. With over 100,000 overdose deaths annually, how do we match the right medication to save each patient's life? Faculty: Smita Das, M.D.
| |||
| Managing OUD with Buprenorphine: Clinical Pearls | 20 Jul 2025 | 00:12:04 | |
In this episode, we explore buprenorphine management for opioid use disorder, covering induction protocols, dosing strategies, and long-term maintenance. Why do patients need to be in withdrawal before starting this life-saving medication, and how can we make this challenging process more manageable? Faculty: Smita Das, M.D. | |||
| Valproate Weight Gain: Do Lower Doses Help? | 15 Jul 2025 | 00:09:18 | |
In this episode, we explore groundbreaking research on valproate's dose-dependent weight gain effects. Could prescribing lower doses be the key to maintaining therapeutic benefits while minimizing one of psychiatry's most challenging side effects? Dr. Paul Zarkowski reveals surprising findings that could transform your valproate prescribing approach. Faculty: Paul Zarkowski, M.D. | |||
| Methadone for Opioid Use Disorder | 10 Jul 2025 | 00:09:27 | |
In this episode, we explore methadone maintenance therapy for opioid use disorder, covering dosing strategies, recent regulatory changes, and safety considerations. Why do so many patients fail on methadone despite its proven effectiveness, and how can proper dosing make the difference between recovery and relapse? Faculty: Smita Das, M.D. | |||
| Clozapine and Compulsions: New Research On An Old Side Effect | 05 Jul 2025 | 00:13:48 | |
In this episode, we explore the puzzling connection between clozapine and obsessive-compulsive symptoms in schizophrenia patients. Does this wonder drug actually cause OCD, or are we missing a deeper story about how protective behaviors transform into compulsive habits? Faculty: Oliver Freudenreich, M.D. | |||
| Naltrexone vs. Topiramate: FDA-Approved vs. Off-Label Options for MAUD | 30 Jun 2025 | 00:10:07 | |
In this episode, we explore groundbreaking head-to-head research comparing topiramate and naltrexone for alcohol use disorder, revealing surprising equivalence in effectiveness. Could the off-label option actually be as good as our FDA-approved standard for treating problematic drinking? Faculty: David Gorelick, M.D. | |||
| Psychedelics and Brain Networks | 23 Sep 2025 | 00:14:11 | |
In this episode, we explore how psychedelics like psilocybin disrupt the brain's default mode network, creating windows of neuroplasticity that correlate with mystical experiences and therapeutic breakthroughs in treatment-resistant depression, anxiety, and addiction. Faculty: Franklin King, M.D. | |||
| Beyond Tapering: Supporting Patients Through Benzodiazepine Discontinuation | 25 Jun 2025 | 00:13:36 | |
In this episode, we discuss the critical challenges of benzodiazepine discontinuation, exploring Benzodiazepine-Induced Neurological Dysfunction (BIND) and effective support strategies for patients experiencing protracted withdrawal. What can clinicians do when over 50% of patients report finding more help from online forums than from medical professionals? Faculty: Alexis Ritvo, M.D. | |||
| Beyond Blood Counts: Clozapine, Bowel Obstruction, and Pneumonia | 20 Jun 2025 | 00:12:48 | |
In this episode, we explore the potentially fatal side effects of clozapine that often receive less attention than agranulocytosis: bowel obstruction and pneumonia. Could your vigilant monitoring of blood counts be overshadowing equally dangerous risks? Faculty: Oliver Freudenreich, M.D. | |||
| Demystifying Benzodiazepine Deprescribing: Smart Approaches to Tapering | 15 Jun 2025 | 00:15:02 | |
In this episode, we discuss evidence-based strategies for safely tapering patients off benzodiazepines, including cut-and-hold and microtapering techniques. What's the best approach when commercial dosage forms limit gradual reductions? Faculty: Alexis Ritvo | |||
| Lithium: Implications for Bone Health | 10 Jun 2025 | 00:10:27 | |
In this episode, we explore lithium's surprising positive effect on bone mineral density in patients with bipolar disorder. Could the medication many psychiatrists use as a mood stabilizer also be protecting patients from osteoporosis? Faculty: Paul Zarkowski, M.D. | |||
| Tapering with Care: Benzodiazepine Discontinuation | 05 Jun 2025 | 00:15:33 | |
In this episode, we explore evidence-based strategies for successful benzodiazepine tapering with addiction psychiatrist Dr. Alexis Ritvo. How can clinicians minimize withdrawal effects while supporting patients through this challenging process? Faculty: Alexis Ritvo, M.D. | |||
| Dementia Risk and Vitamin D | 31 May 2025 | 00:10:51 | |
In this episode, we explore compelling evidence from the UK Biobank showing how vitamin D deficiency may increase dementia risk by up to 25%. Could this affordable supplement be an essential piece of your brain health strategy? Faculty: Scott Beach, M.D.
| |||
| Beyond Benzos: Strategies for Successful Deprescribing | 26 May 2025 | 00:13:41 | |
In this episode, we explore the complex process of benzodiazepine deprescribing, examining when and how to help patients reduce or discontinue these medications. How can clinicians balance the benefits of deprescription against the challenges of withdrawal? Faculty: Alexis Ritvo, M.D. | |||
| Motherhood and Medication: LAIs for Women with Schizophrenia | 21 May 2025 | 00:12:06 | |
In this episode, we explore the unique considerations for using long-acting injectable antipsychotics in women with schizophrenia. How might hormonal fluctuations throughout a woman's life impact treatment decisions for schizophrenia? Faculty: Oliver Freudenreich, M.D. | |||
| Benzodiazepines in High-Risk Populations | 16 May 2025 | 00:09:30 | |
In this episode, we explore the challenges and current guidelines for benzodiazepine use in pregnancy, breastfeeding, and adolescence. When is it appropriate to continue benzodiazepines during pregnancy, and what alternatives should clinicians consider? Faculty: Alexis Ritvo, M.D. | |||
| Benzodiazepines: Understanding Physical Dependence vs. Addiction | 11 May 2025 | 00:12:27 | |
In this episode, we explore benzodiazepine use disorder, distinguishing between physical dependence and addiction while examining practical strategies for safe prescribing. Did you know only 1.5% of benzodiazepine users actually develop a use disorder? Faculty: Alexis Ritvo, M.D. | |||
| LAIs vs Oral Antipsychotics: Mortality Data and Clinical Impact | 18 Sep 2025 | 00:16:33 | |
In this episode, we explore groundbreaking research showing how long-acting injectable antipsychotics can literally save lives in schizophrenia treatment. Could choosing the right medication delivery method be the difference between a patient thriving or facing premature death by 15-20 years? Faculty: Oliver Freudenreich, M.D. | |||
| Beyond Metformin: Probiotics and Antipsychotic Weight Gain | 06 May 2025 | 00:12:46 | |
In this episode, we explore the potential role of the probiotic Akkermansia muciniphila in managing olanzapine-induced weight gain. Could this tiny gut bacterium be the key to maintaining metabolic health while on antipsychotics? Faculty: Oliver Freudenreich, M.D. | |||
| What Every Clinician Should Know About the Risks of Benzodiazepines | 01 May 2025 | 00:09:48 | |
In this episode, we explore the dangerous risks of benzodiazepine use, focusing on the potentially lethal combination with opioids, cognitive impairment, increased accident risk, and fall hazards. Did you know that benzodiazepines combined with opioids increase overdose risk fivefold in the first 90 days? Faculty: Alexis Ritvo, M.D. | |||
| Making an Exit Plan: Navigating Antidepressant Discontinuation | 26 Apr 2025 | 00:11:31 | |
In this episode, we explore the latest research on antidepressant discontinuation symptoms, revealing that about 14% of patients experience these effects when stopping medication. Which antidepressants are most likely to cause these "brain zaps" and other withdrawal symptoms? Faculty: Scott Beach, M.D. | |||
| Clinical Pearls for Selecting the Right Benzodiazepine | 21 Apr 2025 | 00:11:54 | |
In this episode, we discuss the appropriate use of benzodiazepines, focusing on evidence-based indications and optimal medication selection. Did you know that alprazolam has unique properties that make it more addictive than other benzodiazepines? Faculty: Alexis Ritvo, M.D. | |||
| TMS for Depression: From Clinical Trials to Results | 16 Apr 2025 | 00:16:27 | |
In this episode, we explore the evidence behind Transcranial Magnetic Stimulation (TMS) for depression, from early clinical trials to real-world effectiveness. What makes some patients respond better to TMS than others? We discuss response rates, treatment protocols, and the exciting development of faster treatment options. Faculty: Simon Kung, M.D. | |||